Eine multizentrische, randomisierte, offene, aktiv kontrollierte Phase-III-Studie zu DS-8201a (Prüfpräparat) im Vergleich zur Behandlung der Wahl des Arztes (2:1) bei Brustkrebspatienten/-innen/-patienten mit nicht resezierbaren und/oder metastasierenden Tumoren mit niedriger HER2-Expression.

Drug: Trastuzumab deruxtecan (DS-8201a);Drug: Capecitabine;Drug: Eribulin;Drug: Gemcitabine;Drug: Paclitaxel;Drug: Nab-paclitaxel

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- Is the age of majority in their country

- Has pathologically documented breast cancer that:

1. Is unresectable or metastatic

2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)

3. Is HR-positive or HR-negative

4. Has progressed on, and would no longer benefit from, endocrine therapy

5. Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the
recurrent or metastatic setting

6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing
(per American Society of Clinical Oncology-College of American Pathologists
[ASCO-CAP] guidelines)

- Has documented radiologic progression (during or after most recent treatment)

- Has adequate archival tumor samples available or is wiling to provide fresh biopsies
prior to randomization for:

1. assessment of HER2 status

2. assessment of post-treatment status

- Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1

- Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting
functions

- Male and female participants of reproductive/childbearing potential, agrees to follow
instructions for method(s) of contraception and agrees to avoid preserving ova or
sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

- Is ineligible for all options in the physician's choice arm

- Has breast cancer ever assessed with high-HER2 expression

- Has previously been treated with any anti-HER2 therapy, including an antibody drug
conjugate

- Has uncontrolled or significant cardiovascular disease

- Has spinal cord compression or clinically active central nervous system metastases

- Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that
required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that
cannot be ruled out by imaging at screening

- Has any medical history or condition that per protocol or in the opinion of the
investigator is inappropriate for the study